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AbstrAct:
DNA methylation at the 5-position of cytosines (5mC) represents an important 
epigenetic  modification  involved  in  tissue  differentiation  and  is  frequently 
altered in cancer. Recent evidence suggests that 5mC can be converted to 
5-hydroxymethylcytosine (5hmC) in an enzymatic process involving members 
of  the  TET  protein  family.  Such  5hmC  modifications  are  known  to  be  prevalent 
in DNA of embryonic stem cells and in the brain, but the distribution of 5hmC in 
the majority of embryonic and adult tissues has not been rigorously explored. 
Here, we describe an immunohistochemical detection method for 5hmC and the 
application  of  this  technique  to  study  the  distribution  of  5hmC  in  a  large  set  of 
mouse and human tissues. We found that 5hmC was abundant in the majority of 
embryonic and adult tissues. Additionally, the level of 5hmC closely tracked with the 
differentiation state of cells in hierarchically organized tissues. The highest 5hmC 
levels were observed in terminally differentiated cells, while less differentiated 
tissue stem/progenitor cell compartments had very low 5hmC levels. Furthermore, 
5hmC levels were profoundly reduced in carcinoma of the prostate, breast and 
colon compared to normal tissues. Our findings suggest a distinct role for 5hmC 
in tissue differentiation, and provide evidence for its large-scale loss in cancers.
INtrODUctION
Epigenetic  modifications  play  a  crucial  role  in 
cellular  differentiation  and  have  been  implicated  in 
numerous disease states including cancer [1-4]. One of 
the most studied of these modifications is the addition of 
a methyl group on the 5-position of the cytosine (5mC) 
base in a CpG dinucleotide. Accumulation of methylation 
marks  in  CpG  rich  regions  around  the  transcriptional 
start site of genes has been show to be associated with 
alterations in chromatin organization ultimately leading 
to changes in locus specific transcriptional activity [1]. 
Paradoxically, DNA methylation marks can be heritably 
maintained across cell division but can also be reversibly/
dynamically altered to establish new epigenetic programs. 
However, major uncertainties remain on how cells can 
erase existing methylation marks [2, 5, 6].
The recent discovery of a group of enzymes of the 
ten-eleven translocated (TET) family that can specifically 
modify  these  DNA  methylation  marks  by  oxidizing 
5-methylcytosine  (5mC)  to  5-hydroxymethylcytosine 
(5hmC) has added another dimension of complexity to 
our understanding of DNA methylation [7]. It has been 
well established for decades that certain bacteriophages Oncotarget 2011; 2:  627 - 637 628 www.impactjournals.com/oncotarget
contain 5-hydroxymethylcytosine rather than cytosine in 
their genome to protect themselves from host-controlled 
nucleases  [8].  The  presence  of  5hmC  in  mammalian 
cells  has  historically  been  very  controversial,  and  its 
role in mammalian genomes is not well understood [9-
11].  Interestingly,  Penn  et  al.  demonstrated  in  1972 
that  5hmC  can  be  detected  by  crude  chromatography 
methods in rodent brain and liver DNA preparations [11]. 
More  recently,  using  mass  spectrometry,  Kriaucionis 
and Heintz provided firm evidence for the presence of 
5hmC in Purkinje cells of the murine cerebellum [12]. 
Subsequently, several studies have addressed the potential 
role  of  5hmC  and  the  oxidizing  enzymes  of  the  TET 
protein family in genome organization and differentiation 
of murine embryonic stem (ES) cells [13-21]. The tissue 
specific  cellular  distribution  of  5hmC  in  normal  adult 
tissues and neoplasia, however, has thus far not been well-
documented. 
To  address  these  questions,  we  applied  a  novel 
immunohistochemical  staining  method  to  detect  5hmC 
in  a  variety  of  normal  murine  and  human  tissues. 
Interestingly,  we  found  that  in  embryonic  and  adult 
tissues, the abundance of 5hmC correlates with cellular 
differentiation,  with  more  differentiated  cells  showing 
higher  5hmC  staining.  Furthermore,  we  observed  an 
almost  uniform  loss  of  5hmC  levels  in  cancer  tissues 
as  compared  to  their  normal  counterparts,  suggesting 
a complex and yet to be defined role of 5hmC in tissue 
differentiation and neoplasia.
rEsULts
Development and validation of an 
immunohistochemical staining method for global 
analysis of 5hmc levels in situ
Investigation  of  tissue-specific  5hmC  distribution 
has  so  far  been  attempted  by  using  quantitative  mass-
spectrometry  based  methods  or  semi-quantitative 
antibody-based  immunofluorescence  microscopy  [12, 
22].  Unfortunately,  global  5hmC  detection  methods 
involving  processing  of  tissue  lysates  do  not  allow 
the  evaluation  of  5hmC  levels  on  a  cell-by-cell  basis. 
Immunofluorescence microscopy, on the other hand, does 
not allow full morphological evaluation of the tissue and 
is  often  confounded  by  auto-fluorescence  background, 
complicating  interpretation.  We  therefore  aimed  to 
develop  a  method  that  allows  the  immunolabeling 
of  5hmC  with  a  commercially  available  and  recently 
extensively  validated  polyclonal  antibody  [13,  22]  and 
Figure 1: Specificity of immuohistochemical detection of 5hmC. To assess the specificity of 5hmC immuno-labeling of formalin 
fixed paraffin embedded cells, HEK293 cells were transfected with expression plasmids encoding for myc-tagged TET2 or control. Cell 
pellets were fixed and embedded in paraffin. Sections of the resulting paraffin block were co-immuno-labeled with anti-myc and anti-5hmC 
specific antibodies and visualized using fluorophore conjugated secondary antibodies (A, B, C). Note that only cells that express high 
levels of TET2 (indicated by arrowheads) showed strong staining for 5hmC. (D, E) To show that 5hmC can be specifically detected using 
a chromogenic immunohistochemistry method, HEK293 cells overexpressing TET2-myd and HEK293 control cells(E) were stained with 
5hmC specific antibodies and immunocomplexes were visualized using HRP conjugated secondary antibodies with DAB as a chromogen.
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subsequent immunohistochemical detection. To evaluate 
the  specificity  of  the  antibody,  HEK293  cells  were 
transiently transfected with expression vectors encoding 
myc-tagged TET2 or control (Figure 1). Cells were fixed 
in 10% buffered formalin and embedded in paraffin as 
described previously [23]. Sections of the obtained cell 
block were then double-immunolabeled with 5hmC and 
myc-tag specific antibodies. As shown previously [24], 
cells  expressing  TET2  (arrowheads)  showed  strong 
nuclear 5hmC staining providing a robust positive control 
for staining optimization (Figure 1 A, B, C). Conversely, 
HEK293 not expressing TET2myc and control HEK293 
cells did not exhibit strong staining for 5hmC. Next, TET2 
expressing and control HEK293 cells were incubated with 
5hmC  antibodies;  immunocomplexes  were  visualized 
using HRP conjugated secondary antibodies with DAB 
as a chromogen. Cells expressing TET2 showed a strong 
nuclear signal for 5hmC, whereas control transected cells 
only showed very faint to undetectable nuclear staining. 
The low intensity of staining in the control cells likely 
reflects the low levels of 5hmC previously observed in 
HEK293 cells [25]. Our pretreatment protocol included 
two antigen retrieval steps: a 30 min steaming in citrate 
buffer (ph 6.0) and a 15 min incubation in 3.5 N HCl. Both 
steps were required for efficient immunolabeling of 5hmC 
in formalin fixed paraffin embedded material; omission 
of the citrate steam and/or HCl steps resulted in almost 
complete  absence  of  5hmC  staining  (Supplementary 
Figure 1), highlighting the importance of adequate antigen 
unmasking for immunohistochemical analysis.
Distribution of 5hmc content in mouse embryonic 
tissues
We first determined the 5hmC staining pattern in 
the developing mouse embryo. Seventeen-day-old mouse 
embryos were fixed, paraffin embedded, and processed as 
outlined below. In line with recent reports, we detected 
significant levels of 5hmC in the mouse cerebral cortex 
and cerebellum [12, 22, 26]. In addition, 5hmC was also 
detectable in the majority of tissues throughout the mouse 
embryo. Interestingly, we observed a strong association 
of 5hmC content with the differentiation state of cells in 
many  hierarchically  organized  tissues.  For  instance,  in 
the intestine of the embryo, cells lining the crypts of the 
mucosa showed almost no staining for 5hmC, whereas 
more apical cells exhibited strong staining (Figure 2A). 
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Figure 2: 5hmC is abundant in embryonal and adult tissues, with differential abundance in basal vs. luminal cell 
compartments of stratified epithelia. Micrographs show 5hmC staining in the intestine (A) and skin (B) of a 17 day old mouse embryo. 
Note the reduced staining of 5hmC staining in the basal cell compartment (indicated by arrowheads) compared to the luminal/apical 
epithelial cells (indicated by arrows). (C) Normal human adult colonic mucosa exhibits strong staining for 5hmC in apical epithelial cells 
(indicated by arrows); epithelial cells in the base of the crypt (indicated by arrowheads) show greatly reduced staining intensities. Note the 
strong 5hmC staining of associated stromal nuclei. (D) Hierarchical distribution of 5hmC staining in murine cervix. Asterisk (*) indicates 
apical/luminal surface.Oncotarget 2011; 2:  627 - 637 630 www.impactjournals.com/oncotarget
Similarly, the skin in the developing mouse embryo also 
showed  a  hierarchical  distribution  of  5hmC  staining, 
with  cells  in  the  basal  epithelial  layer  showing  very 
low  staining  intensities  and  more  apical  cells  staining 
strongly for 5hmC (Figure 2B). These patterns suggest 
that in the developing embryo, 5hmC is more abundant 
in more differentiated cell compartments than in the less 
differentiated cell compartments.
5hmc content is generally correlated with 
differentiation state of cells in hierarchically 
organized mouse and human adult tissues
To  test  whether  this  association  of  5hmC  with 
differentiation in hierarchically organized tissues would 
also  be  maintained  in  adult  tissues,  we  investigated 
several tissue types from adult mice and humans. Human 
colon represents a classical model for hierarchical tissue 
differentiation.  Cells  at  the  base  of  the  colonic  crypt 
proliferate  and  represent  the  regenerative  tissue  stem/
progenitor cell compartment [27, 28]. Conversely, cells 
in  the  luminal  side  of  the  colon  form  the  terminally 
differentiated cell compartment. Interestingly, we found 
that  this  hierarchical  differentiation  is  associated  with 
strong differences in 5hmC levels. Whereas apical cells 
of the colonic mucosa show strong 5hmC staining, cells 
in the base of the crypts had greatly reduced 5hmC levels 
(Figure  2C).  Other  stratified  epithelia,  including  that 
in cervix, oral mucosa, and bladder, exhibited a similar 
distribution of 5hmC staining in which apical cells showed 
higher 5hmC levels as compared to basal cells (Figure 2, 
Supplementary Figure 2).
To  assess  this  differential  distribution  more 
rigorously  and  quantitate  5hmC  levels  in  luminal  and 
basal  cell  compartments,  we  used  immunofluorescence 
microscopy  coupled  with  quantitative  image  analysis. 
Slides containing normal human prostate or normal human 
esophagus were co-immunolabeled with 5hmC antibodies 
and basal cell specific cytokeratin antibodies (34βE12-903 
for prostate, CK15 for esophagus) [29]. Signal intensities 
of  5hmC  were  determined  in  basal  and  luminal/apical 
cell  compartments  (Figure  3)  using  quantitative  image 
analysis software. We observed a statistically significant 
difference in 5hmC staining intensities between basal and 
luminal cells for prostate (median signal intensity values: 
basal 0, luminal 118, p < 0.0001) and esophageal epithelia 
(median signal intensity values: basal 53.6, luminal 555.2, 
p  <  0.0001)  providing  a  quantitative  validation  of  the 
differential distribution of 5hmC in these tissues (Figure 
3).
5hmc levels are reduced in hematopoietic 
stem and progenitor cells compared to more 
differentiated counterparts
Although not necessarily hierarchically organized by 
location of cell compartments, hematopoietic cells in the 
bone marrow show a distinct hierarchy of differentiation. 
Well-defined markers allow the cell compartment specific 
enrichment of undifferentiated stem cells, progenitor cells, 
and terminally differentiated mature blood cells [30, 31]. 
Using  FACS,  hematopoietic  stem  cells  (CD34+;CD38-
Figure 3: Quantitative analysis of the hierarchical distribution of 5hmC in stratified epithelia. (A-C) Representative 
micrographs of normal prostate epithelia co-immunolabeled for 5hmC (red) and basal cell specific cytokeratin 903 (green). Nuclei were 
counterstained with DAPI (blue). (D) Box-plots show the distribution of 5hmC fluorescence intensities in basal (903+) and luminal (903-) 
cells, normalized to DAPI. (E-G) Representative micrographs of normal esophageal mucosa co-immunolabeled for 5hmC (red) and basal 
cell specific CK15 (green). (H) Distribution of 5hmC staining intensities in basal (CK15+) and luminal (CK15-) cells, normalized to DAPI. 
Arrowheads indicate basal cells, arrows indicate luminal cells, Asterisks (*) indicate lumen. 
C D AB
* * *
G F E * * * H
Esophagus
Figure 3.
0
2
0
0
4
0
0
6
0
0
8
0
0
1
0
0
0
0
5
0
1
0
0
1
5
0
2
0
0
2
5
0
Basal Luminal
Prostate
5
h
m
C
 
s
t
a
i
n
i
n
g
 
i
n
t
e
n
s
i
t
i
e
s
 
n
o
r
m
a
l
i
z
e
d
 
t
o
 
D
A
P
I
Esophagus
5
h
m
C
 
s
t
a
i
n
i
n
g
 
i
n
t
e
n
s
i
t
i
e
s
 
n
o
r
m
a
l
i
z
e
d
 
t
o
 
D
A
P
I
Prostate P < 0.001
P < 0.001
merge
5hmC
DAPI
5hmC
DAPI
Basal Luminal
5hmC
903
merge
5hmC
CK15Oncotarget 2011; 2:  627 - 637 631 www.impactjournals.com/oncotarget
;ALDH+)  and  progenitor  cells  (CD34+;CD38+)  were 
sorted as described previously [32]. Cells were then stained 
with 5hmC specific antibodies and staining intensities in 
hematopoietic stem and progenitor cells were compared to 
more differentiated bone marrow cells that were depleted 
of CD34 positive cells (Figure 4, Supplementary Figure 
3).  Consistent  with  what  was  observed  for  stratified 
epithelial  tissues  as  described  above,  hematopoietic 
stem  and  progenitor  cell  populations  exhibited  much 
lower 5hmC content than their more differentiated CD34 
negative counterparts (Figure 4; p < 0.001).
Loss of 5hmc in human cancers
Tumors often adopt a caricaturized differentiation 
phenotype  consisting  of  loss  of  some  features  of 
differentiation and gain of certain functions, such as self-
renewal, that are more characteristic of less differentiated 
stem  cells  [33];  these  changes  are  nearly  universally 
associated with profound epigenetic alterations [3, 4, 34]. 
We  assessed  whether  tumor  cells  have  5hmC  contents 
closer  to  terminally  differentiated  cells  or  to  tissue 
stem cell compartments from their tissue of origin. To 
determine the levels and distribution of 5hmC in cancer 
and normal tissues, we assessed a total of 78 carcinoma 
and 28 normal tissue samples from prostate, breast, and 
colon (Figure 5). Analysis of this set of normal tissues 
confirmed the general pattern of increased 5hmC content 
in more differentiated cell types in the normal prostate 
and colon; terminally differentiated luminal cells in these 
tissues showed much stronger 5hmC staining than basal 
cells, the likely compartment containing the tissue stem/
progenitor cells [27, 28, 35, 36] (Figure 5A,G). In breast 
tissue, the identity of the undifferentiated tissue stem cell 
compartment  is  more  controversial  [37].  We  observed 
that  the  myoepithelial  cells  in  normal  breast  glands 
tended to show a subtle, but noticeable, stronger 5hmC 
staining  than  the  normal  luminal  cells.  Nonetheless, 
comparing these normal tissues to cancers arising from 
the same tissues, we observed a profound reduction in 
5hmC content in the cancers for all three tumor types 
(p < 0.001 for prostate and breast; p = 0.001 for colon). 
Interestingly, in prostate tissues, where we could observe 
normal  prostate  glands  adjacent  to  malignant  glands, 
we saw a significant reduction in 5hmC staining in the 
cancerous glands compared to the adjacent normal glands 
(Figure 5A arrowheads). 5hmC staining intensities were 
not associated with clinicopathological features such as 
grade and stage. Even small lesions of low histological 
grade showed profound reduction of 5hmC. This suggests 
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Figure 4: Quantitative analysis of the hierarchical distribution of 5hmC in hematopoietic cells. Ficoll-Paque enriched, 
CD34-depleted bone marrow, or FACS sorted CD34+;CD38-;ALDH-high hematopoietic stem cells, or CD34+;CD38+ progenitor cells 
were spotted on glass slides, stained with 5hmC specific antibodies and visualized using immunofluorescence microscopy. Signal intensities 
were determined by quantitative image analysis. (A) Distribution of 5hmC signal intensities in the stem cell (CD34 positive ALDH high), 
progenitor cell (CD34, CD38 positive) and differentiated cell (CD34 negative) compartments. (B) Representative micrographs of each 
enriched fraction.Oncotarget 2011; 2:  627 - 637 632 www.impactjournals.com/oncotarget
that the global loss of 5hmC could be an early event in 
carcinogenesis.
Since  5mC  is  the  substrate  for  the  TET-enzyme 
mediated conversion to 5hmC, the global loss of 5hmC 
seen here could simply reflect a decrease in 5mC levels, 
which is known to occur in human cancers. Therefore, we 
assessed 5mC levels in normal and tumor tissues from 
the colon and the prostate using a previously validated 
immunohistochemical  staining  method  that  specifically 
detects 5mC [38] (Supplementary Figure 4). As compared 
to normal tissue, adenocarcinoma of the colon and the 
prostate  only  showed  a  very  modest  decrease  in  5mC 
intensities (Supplementary Figure 4), and we observed no 
correlation between 5hmC and 5mC. These data suggest 
that the global decrease of 5mC cannot alone account for 
the profound loss of 5hmC levels in solid tumors.
DIscUssION
The recent finding that oxidation of 5mC to 5hmC 
by enzymes of the ten-eleven translocated (TET) family 
occurs in mammalian genomes has raised many questions 
regarding the role of this DNA modification in epigenetic 
regulation. Even though several studies have investigated 
the complex role of TET proteins and 5hmC in embryonic 
stem cell biology, the relevance of this mark in developing 
normal and adult tissues remained essentially unexplored.
Here,  we  developed  a  novel,  robust 
immunohistochemical  detection  method  for  5hmC  and 
used this method to detect 5hmC in a large number of 
murine and human tissues. Interestingly, we found that 
hierarchically organized epithelia as well as hematopoietic 
cells in the bone marrow show a differentiation-dependent 
5hmC distribution. Cells in the colonic crypt, basal cells 
Figure 5: Significant reduction in 5hmC levels in cancers. Micrographs of representative 5hmC staining in normal human prostate 
(A) and prostate adenocarcinoma (B), normal breast (D) and ductal breast cancer (E) and normal colon mucosa (G) and adenocarcinoma 
of the colon (H). (C, F, I) show distributions of semi-quantitative intensities scores in normal and tumor cells in box-and-whisker plots. 
Note that (A) contains a small focus of cancerous glands (indicated by arrowheas) infiltrating normal prostatic epithelium. Arrows indicate 
normal epithelial cells; arrowheads show tumor cell nuclei with reduced 5hmC staining.
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of the prostate, as well as hematopoietic stem/progenitor 
cells exhibited greatly reduced 5hmC levels compared to 
more  differentiated  counterparts,  suggesting  that  adult 
tissue  stem/progenitor  cells  across  a  broad  range  of 
tissue types might be characterized by low 5hmC levels. 
Differentiation  and  maturation  conversely  appeared  to 
be associated with an increase in 5hmC. Based on these 
data, we can hypothesize that accumulation of 5hmC in 
the genome is involved in differentiation of tissue stem/
progenitor cells. This hypothesis is supported by recent 
reports  showing  that  genetic  disruption  of  TET2  in 
hematopoietic cells could lead to increased hematopoietic 
stem  cell  self-renewal,  accumulation  of  hematopoietic 
stem/progenitor  cells,  and  reduced  differentiation  of 
hematopoietic stem cells [39, 40].
This observation is somewhat in contrast to recent 
reports  from  murine  embryonic  stem  cells,  where 
the  differentiation  of  embryonic  stem  cells  appeared 
to  be  associated  with  a  loss  in  5hmC  [24,  26].  These 
discrepancies  could  reflect  differences  in  the  biology 
between embryonic and tissue stem cells and could point 
to a differential role of 5hmC in very early development 
versus later development and adult tissue development/
differentiation.
Recent reports on the detection of 5hmC in adult 
tissues  have  been  somewhat  conflicting  [22,  26].  One 
explanation for these variable results is certainly the use 
of different detection methods. In this study, we noted that 
robust  immunohistochemical  detection  of  5hmC  from 
formalin fixed paraffin embedded tissue requires specific 
antigen  retrieval.  Omission  of  these  antigen  retrieval 
steps  led  to  vastly  different  results  (Supplementary 
Figure 1) and, therefore, explained some of the prevailing 
discrepancies in the literature.
The  functional  role  of  5hmC  in  regulating 
differentiation  and  epigenetic  states  of  adult  tissues 
remains unknown. It has been proposed that 5hmC cannot 
be  bound  by  methyl-binding  domain  proteins  such  as 
MeCP2, MBD1, and MBD2 [41-43], which are known to 
associate with 5mC and recruit the chromatin repression 
complex. Accumulation of 5hmC could therefore have a 
significant impact on gene expression states. Moreover, it 
was suggested that 5hmC is not recognized by the DNA 
methylation maintenance machinery, suggesting that the 
presence of 5hmC could lead to a passive loss of DNA 
methylation during cell division [44]. Most interestingly 
however,  the  conversion  of  5mC  to  5hmC  could  also 
represent  a  mechanism  for  active  demethylation.  In 
a  process  that  involves  activation  induced  deaminase 
(AID) and base excision repair, 5hmC can be converted 
to  cytosine  [45,  46],  providing  a  mechanism  for  the 
sequential, active conversion of 5mC to cytosine. Such a 
process provides an interesting mechanism for plasticity 
of DNA methylation marks. 
Our observation that 5hmC levels are significantly 
reduced  in  three  different  types  of  human  carcinoma 
suggests that the loss of 5hmC could be a general feature 
of  carcinogenesis.  Indeed,  in  several  hematological 
malignancies including AML and MDS, reduced 5hmC 
levels have been associated with mutations in the TET 
genes  [47,  48].  However,  it  is  unlikely  that  missense 
mutation  in  the  TET  enzymes  can  explain  the  almost 
universal reduction in 5hmC levels in colorectal, prostate 
and breast carcinoma, since large scale sequencing efforts 
have not identified TET family members as frequently 
mutated in these tumors [49-52]. Recent evidence suggests 
that a large number of oxidizing enzymes, including the 
TET family, can be inhibited by oncogenic metabolites, 
such  as  2-hydroxyglutarate  [53,  54].  It  is,  therefore, 
possible  that  cancer  specific  metabolic  perturbations 
can influence 5hmC levels and, consequently, alter the 
epigenetic makeup of a cell.
In  many  solid  tumors,  cancer  progression  is 
associated with a progressive loss of 5mC marks resulting 
in  a  global  hypomethylation  phenotype  [3,  4].  Since 
5mC is required as a substrate for oxidation to generate 
5hmC, reduced 5mC levels could explain, at least partly, 
the  decrease  of  5hmC  observed  in  tumors. To  address 
a possible correlation between 5hmC and 5mC loss we 
stained a series of tumor and normal tissues from prostate 
and colon with an antibody that specifically recognizes 
5mC (Supplementary Figure 4). Using this method, we 
observed only a modest reduction of global 5mC staining 
intensities between cancerous and normal tissue of the 
colon and prostate, which is inline with recent reports [38, 
55, 56]. Furthermore, we found no association between 
5mC  and  5hmC  staining  levels  suggesting  that  the 
reduction in 5hmC can occur independently of reductions 
in 5mC.
In  conclusion,  our  study  identifies  a  hierarchical 
distribution of 5hmC levels in embryonic and adult tissues 
and  provides  evidence  for  a  cancer-associated  loss  of 
5hmC.
MAtErIALs AND MEtHODs
sample materials
Mouse embryo tissue was obtained from seventeen-
day-old  C57BL  embryos.  All  remaining  normal  adult 
mouse  tissues  were  from  11  week  old  FVB  mice. All 
tissues were fixed in 10% buffered formalin immediately 
after  tissue  harvest  and  were  embedded  into  paraffin. 
Tissue microarrays containing normal and tumor tissue 
form prostate, breast and colon were constructed at the 
Johns Hopkins TMA core facility.
Pathological evaluation 
Samples were assessed by using an H-score system Oncotarget 2011; 2:  627 - 637 634 www.impactjournals.com/oncotarget
obtained by multiplying the intensity of the stain (0: no 
staining; 1: weak staining; 2: moderate staining; 3: intense 
staining) by the percentage (0 to 100) of cells showing that 
staining intensity (H-score range, 0 to 300). Only nuclear 
staining in epithelial cells was evaluated, either in tumor or 
benign tissues. Since nuclear 5hmC staining was robustly 
detected in stromal cells associated with tumor or benign 
tissue, only samples with strong stromal staining were 
evaluated as a means of censoring tissue samples that did 
not stain for 5hmC due to fixation or other artifacts.
Immuno-labeling of 5hmc and 5mc
To  generate  positive  controls  for  5hmC  staining 
optimization, HEK293 cells were transiently transfected 
with myc-tagged TET2 constructs (obtained from Dr. Ari 
Melnick [53]) or vector controls using Lipofectamine 2000 
(Invitrogen, Carlsbad, CA). Cell pellets were fixed in 10% 
buffered formalin and embedded in paraffin as described 
previously [23]. 5 micron paraffin sections were de-waxed 
and  rehydrated  following  standard  protocols.  Antigen 
retrieval consisted of steaming for 30 min in citrate buffer 
(pH 6.0) followed by incubation in 3.5 N HCl for 15 min 
at room temperature. Slides were washed and equilibrated 
in TBS-Tween buffer (Sigma, St. Louis, MO) for 10 min. 
The same antigen retrieval was used for 5mC and 5hmC. 
For  immunolabeling  of  5hmC,  the  rabbit  polyclonal  5 
hydroxymethylcytosine specific antibody (Active Motif, 
Cat  #  39769,  Carlsbad,  CA)  was  applied  at  1:20,000 
dilution.  For  5mC  detection,  the  mouse  monoclonal  5 
methylcytosine  specific  antibody  (Calbiochem,  EMD 
Chemicals  Inc.,  San  Diego,  CA)  was  used  at  1:2000 
dilution. Both primary antibodies were incubated for 1 h 
at room temperature. Immuno-complexes were detected 
using  the  the  PowerVision+™  immunohistochemistry 
detection  system  from  ImmunoVision  Technologies 
Co  (Norwell,  MA,  USA)  with  3,3′-diaminobenzidine 
tetrahydrochloride  (DAB)  as  the  chromogen.  After 
immunohistochemical  staining,  tissue  sections  were 
counterstained with hematoxylin.
For  immunofluorescence  analysis,  slides  were 
pretreated as outlined above and incubated with rabbit 
polyclonal  5hmC  specific  antibody  (Active  Motif,  Cat 
#  39769)  at  a  1:8000  dilution  with  or  without  mouse 
monoclonal antibodies specific to myc (9E11, Santa Cruz, 
CA), cytokeratin 34βE12-903 (ENZO, Farmingdale, NY) 
or cytokeratin 15 (Ab-1, NeoMarkers, Fremont, CA ) at 
1:50 dilutions. Immuno-complexes were further labeled 
with secondary antibodies conjugated with Alexa 488 or 
Alexa 568 dyes (Invitrogen) and DNA was counterstained 
with DAPI. Slides were then visualized using a Nikon 
E400  fluorescence  microscope  (Nikon  Instruments, 
Melville, NY).
To  quantitate  5hmC  levels  in  different  cell 
compartments, representative images of 5hmC and 903 or 
CK15 co-labeled slides were analyzed using the Telometer 
software application [57]. Therefore, signal intensities of 
individual cell nuclei in the basal and luminal/apical cell 
compartment were determined. To account for differences 
in  overall  DNA  content,  5hmC  signal  intensities  were 
normalized to DAPI intensities.
Isolation of hematopoietic cells
Hematopoietic  stem  and  progenitor  cells  were 
isolated  as  described  previously  [32].  In  brief,  bone 
marrow samples were obtained from healthy individuals 
and mononuclear cells were isolated from fresh samples by 
Ficoll-Paque density centrifugation. To enrich for CD34 
positive cell populations, cells were selected by Miltenyi 
Biotec  columns  (Auburn,  CA).  CD34  negative  cells 
were spotted on glass slides. Aldehyde Dehydrogenase 
(ALDH) activity was assessed in CD34 positive cells by 
staining  with Aldefluor  (Aldagen,  Durham,  DC).  Cells 
were further immuno-labeled with anti-CD34 and anti-
CD38 antibodies, sorted into CD34+CD38−ALDHhigh and 
CD34+CD38+ fractions and directly spotted on microscope 
slides.  Samples  were  then  stained  with  5hmC  specific 
antibodies.
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